Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC)

BACKGROUND: Advanced gastric signet-ring cell carcinoma (SRCC) is a specific type of malignant gastric cancer (GC) with distinct poorer survival. Claudin18.2 (CLDN18.2) is a promising neo-biomarker for the treatment of GC. Clinical trials of CLDN18.2-targeted antibody and T cell-based immunotherapy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastrointest Oncol
Autors principals: Xu, Bo, Liu, Fangcen, Liu, Qin, Shi, Tao, Wang, Zhongda, Wu, Nandie, Xu, Xinyun, Li, Lin, Fan, Xiangshan, Yu, Lixia, Liu, Baorui, Wei, Jia
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7807267/
https://ncbi.nlm.nih.gov/pubmed/33457012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo-20-344
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars